期刊
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
卷 1863, 期 7, 页码 1717-1727出版社
ELSEVIER
DOI: 10.1016/j.bbamcr.2016.03.003
关键词
Drug discovery; High content screening; Cardiomyocyte; Heart; Physiology; Automated microscopy; Particle image velocimetry
资金
- NHLBI NIH HHS [R01 HL128630, R01 HL054732, R01 HL113601, R01 HL128072, 5R01 HL113601, 1R01 HL128072] Funding Source: Medline
- NIGMS NIH HHS [R01 GM084227, 1R01 GM084227] Funding Source: Medline
- Div Of Chem, Bioeng, Env, & Transp Sys
- Directorate For Engineering [1055697] Funding Source: National Science Foundation
Cardiac drug discovery is hampered by the reliance on non-human animal and cellular models with inadequate throughput and physiological fidelity to accurately identify new targets and test novel therapeutic strategies. Similarly, adverse drug effects on the heart are challenging to model, contributing to costly failure of drugs during development and even after market launch. Human induced pluripotent stem cell derived cardiac tissue represents a potentially powerful means to model aspects of heart physiology relevant to disease and adverse drug effects, providing both the human context and throughput needed to improve the efficiency of drug development. Here we review emerging technologies for high throughput measurements of cardiomyocyte physiology, and comment on the promises and challenges of using iPSC-derived cardiomyocytes to model disease and introduce the human context into early stages of drug discovery. This article is part of a Special Issue entitled: Cardiomyocyte biology: Integration of Developmental and Environmental Cues in the Heart edited by Marcus Schaub and Hughes Abriel. (c) 2016 Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据